Trends in Cardiovascular Medicine
Volume 16, Issue 4 , Pages 118-124 , May 2006

Endothelial Dysfunction and Impaired l-arginine Transport in Hypertension and Genetically Predisposed Normotensive Subjects

  • Zhiyong Yang
    • ,
  • David M. Kaye

      Affiliations

    • Corresponding Author InformationAddress correspondence to: David M. Kaye, Baker Heart Research Institute, PO Box 6492, St Kilda Rd Central, Melbourne VIC 8008, Australia. Tel.: (+61) 3-9207-1044; fax: (+61) 3-9207-1075

References 

  1. Ahlers BA, Parnell MM, Chin-Dusting JP, Kaye DM. An age-related decline in endothelial function is not associated with alterations in l-arginine transport in humans. J Hypertens. 2004;22:321–327
  2. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:413–420
  3. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43:521–531
  4. Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int Suppl. 2003;S50–S53
  5. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108:2000–2006
  6. Bolotina VM, Najibi S, Palacino JJ, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature. 1994;368:850–853
  7. Brancati FL, Kao WH, Folsom AR, et al. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253–2259
  8. Bucci M, Gratton JP, Rudic RD, et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000;6:1362–1367
  9. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-l-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10:1025–1031
  10. Caulfield M, Munroe P, Pembroke J, et al. Genome-wide mapping of human loci for essential hypertension. Lancet. 2003;361:2118–2123
  11. Chen PY, Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension. 1993;22:812–818
  12. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527–3561
  13. Closs EI, Lyons CR, Kelly C, Cunningham JM. Characterization of the third member of the MCAT family of cationic amino acid transporters. Identification of a domain that determines the transport properties of the MCAT proteins. J Biol Chem. 1993;268:20796–20800
  14. Closs EI, Graf P, Habermeier A, et al. Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: three related carriers with distinct transport properties. Biochemistry. 1997;36:6462–6468
  15. Cockcroft JR, Chowienczyk PJ, Benjamin N, et al. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med. 1994;330:1036–1040
  16. De Champlain J, Wu R, Girouard H, et al. Oxidative stress in hypertension. Clin Exp Hypertens. 2004;26:593–601
  17. De Meyer GRY, Herman AG. Nitric oxide and vascular endothelial dysfunction. In:  Ignarro LJ editors. Nitric oxide biology and pathobiology. San Diego: Academic; 2000;p. 547–569
  18. Dye JF, Vause S, Johnston T, et al. Characterization of cationic amino acid transporters and expression of endothelial nitric oxide synthase in human placental microvascular endothelial cells. FASEB J. 2004;18:125–127
  19. Fernandez J, Lopez AB, Wang C, et al. Transcriptional control of the arginine/lysine transporter, cat-1, by physiological stress. J Biol Chem. 2003;278:50000–50009
  20. Gaeta G, De Michele M, Cuomo S, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med. 2000;343:840–846
  21. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell. 2001;106:403–411
  22. Gold ME, Bush PA, Ignarro LJ. Depletion of arterial l-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun. 1989;164:714–721
  23. Guzik TJ, Black E, West NE, et al. Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet. 2001;100:130–137
  24. Heller R, Unbehaun A, Schellenberg B, et al. l-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 2001;276:40–47
  25. Hemmens B, Mayer B. Enzymology of nitric oxide synthases. Methods Mol Biol. 1998;100:1–32
  26. Hingorani AD. Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep. 2003;5:19–25
  27. Izawa H, Yamada Y, Okada T, et al. Prediction of genetic risk for hypertension. Hypertension. 2003;41:1035–1040
  28. Jachymova M, Horky K, Bultas J, et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun. 2001;284:426–430
  29. Jin JJ, Nakura J, Wu Z, et al. Association of endothelin-1 gene variant with hypertension. Hypertension. 2003;41:163–167
  30. Jones LC, Hingorani AD. Genetic regulation of endothelial function. Heart. 2005;91:1275–1277
  31. Jones LC, Tran CT, Leiper JM, et al. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun. 2003;310:836–843
  32. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511–2517
  33. Kamada Y, Nagaretani H, Tamura S, et al. Vascular endothelial dysfunction resulting from l-arginine deficiency in a patient with lysinuric protein intolerance. J Clin Invest. 2001;108:717–724
  34. Kamide K, Kokubo Y, Yang J, et al. Hypertension susceptibility genes on chromosome 2p24-p25 in a general Japanese population. J Hypertens. 2005;23:955–960
  35. Katusic ZS. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?. Am J Physiol Heart Circ Physiol. 2001;281:H981–H986
  36. Kaye DM, Parnell MM, Ahlers BA. Reduced myocardial and systemic l-arginine uptake in heart failure. Circ Res. 2002;91:1198–1203
  37. Kim YM, Bombeck CA, Billiar TR. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res. 1999;84:253–256
  38. Knowles R, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298:249–258(Pt 2)
  39. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des. 2002;8:155–166
  40. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282–1288
  41. Li H, Meininger CJ, Hawker JR, et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2001;280:E75–E82
  42. Lifton RPL. Molecular genetics of human blood pressure variation. Science. 1996;272:676–680
  43. Linke A, Recchia F, Zhang X, Hintze TH. Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev. 2003;8:87–97
  44. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. Am J Cardiol. 2005;96:13i–24i
  45. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev. 2003;83:183–252
  46. Marteau JB, Zaiou M, Siest G, Visvikis-Siest S. Genetic determinants of blood pressure regulation. J Hypertens. 2005;23:2127–2143
  47. Maxwell AJ, Cooke JP. Cardiovascular effects of l-arginine. Curr Opin Nephrol Hypertens. 1998;7:63–70
  48. McAllister AS, Atkinson AB, Johnston GD, et al. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond). 1999;97:141–147
  49. McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics. 2004;14:831–839
  50. Mein CA, Caulfield MJ, Dobson RJ, Munroe PB. Genetics of essential hypertension. Hum Mol Genet. 2004;13:R169–R175(Spec No 1)
  51. Nassar BA, Bevin LD, Johnstone DE, et al. Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. Am Heart J. 2001;142:586–589
  52. Ou W, Silver J. Role of a conserved amino-terminal sequence in the ecotropic MLV receptor mCAT1. Virology. 2003;308:101–113
  53. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468–1474
  54. Panza JA, Garcia CE, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732–1738
  55. Persu A, Stoenoiu MS, Messiaen T, et al. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet. 2002;11:229–241
  56. Perticone F, Sciacqua A, Scozzafava A, et al. Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab. 2004;89:3606–3609
  57. Preli RB, Klein KP, Herrington DM. Vascular effects of dietary l-arginine supplementation. Atherosclerosis. 2002;162:1–15
  58. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;276:38121–38138
  59. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899–1906
  60. Schlaich MP, Parnell MM, Ahlers BA, et al. Impaired l-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004;110:3680–3686
  61. Schneider MP, Hilgers KF, Huang Y, et al. The C242T p22phox polymorphism and endothelium-dependent vasodilation in subjects with hypercholesterolaemia. Clin Sci (Lond). 2003;105:97–103
  62. Siani A, Pagano E, Iacone R, et al. Blood pressure and metabolic changes during dietary l-arginine supplementation in humans. Am J Hypertens. 2000;13:547–551
  63. Sobrevia L, Mann GE. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Physiol. 1997;82:423–452
  64. Stangl K, Cascorbi I, Laule M, et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics. 2000;10:133–140
  65. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91:1981–1987
  66. Taddei S, Virdis A, Mattei P, et al. Defective l-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation. 1996;94:1298–1303
  67. Tanira MO, Al Balushi KA. Genetic variations related to hypertension: a review. J Hum Hypertens. 2005;19:7–19
  68. Tsujita Y, Baba S, Yamauchi R, et al. Association analyses between genetic polymorphisms of endothelial nitric oxide synthase gene and hypertension in Japanese: the Suita Study. J Hypertens. 2001;19:1941–1948
  69. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens. 1998;11:125–128
  70. Wu G, Flynn NE, Flynn SP, et al. Dietary protein or arginine deficiency impairs constitutive and inducible nitric oxide synthesis by young rats. J Nutr. 1999;129:1347–1354

PII: S1050-1738(06)00034-X

doi: 10.1016/j.tcm.2006.02.003

Trends in Cardiovascular Medicine
Volume 16, Issue 4 , Pages 118-124 , May 2006

Article Tools